United Therapeutics Corp.

Founded by our Chairperson and Chief Executive Officer, Martine Rothblatt, to find a cure for her daughter’s life-threatening rare disease, pulmonary arterial hypertension ( PAH ), United Therapeutics advances therapies for people living with serious diseases with unmet medical needs. Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies. As a public benefit corporation ( PBC ), we aim to deliver meaningful impacts for our patients, our people, our shareholders, and other stakeholders. Our public benefit purpose, as outlined in our charter and approved by our shareholders, is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs . We market and sell the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder ( Tyvaso DPI ); Tyvaso (treprostinil) Inhalation Solution ( Nebulized Tyvaso ), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection ( Remodulin ); and the Remunity and RemunityPRO Pumps for Remodulin ( Remunity ); Orenitram (treprostinil) Extended-Release Tablets ( Orenitram ); and Adcirca (tadalafil) Tablets ( Adcirca ). Tyvaso DPI and Nebulized Tyvaso are also approved by the U.S. Food and Drug Administration ( FDA ) to treat pulmonary hypertension associated with interstitial lung disease ( PH-ILD ).